MX2019012336A - Compuestos inhibidores del transportador vesicular de monoaminas 2 (vmat2) y composiciones de los mismos. - Google Patents

Compuestos inhibidores del transportador vesicular de monoaminas 2 (vmat2) y composiciones de los mismos.

Info

Publication number
MX2019012336A
MX2019012336A MX2019012336A MX2019012336A MX2019012336A MX 2019012336 A MX2019012336 A MX 2019012336A MX 2019012336 A MX2019012336 A MX 2019012336A MX 2019012336 A MX2019012336 A MX 2019012336A MX 2019012336 A MX2019012336 A MX 2019012336A
Authority
MX
Mexico
Prior art keywords
sup
compounds
compositions
inhibitor compounds
vmat2 inhibitor
Prior art date
Application number
MX2019012336A
Other languages
English (en)
Inventor
Nicole Harriott
Donald Hettinger
Shawn Branum
Jeffrey C Culhane
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62111264&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019012336(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of MX2019012336A publication Critical patent/MX2019012336A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporciona un compuesto seleccionado de compuestos de fórmula (I) y sales, solvatos e hidratos farmacéuticamente aceptables de los mismos: (Ver formula) en la que R1, R2, R3 y R4 son tal como se definen en el presente documento. Tales compuestos son inhibidores del transportador vesicular de monoaminas 2 (VMAT2) y tienen utilidad para tratar, por ejemplo, enfermedades y trastornos neurológicos y psiquiátricos. También se dan a conocer composiciones que contienen tales compuestos en combinación con un portador farmacéuticamente aceptable, así como métodos relativos a su uso en sujetos que lo necesitan.
MX2019012336A 2017-04-19 2018-04-17 Compuestos inhibidores del transportador vesicular de monoaminas 2 (vmat2) y composiciones de los mismos. MX2019012336A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762487413P 2017-04-19 2017-04-19
US201862652837P 2018-04-04 2018-04-04
PCT/US2018/028031 WO2018195121A1 (en) 2017-04-19 2018-04-17 Vmat2 inhibitor compounds and compositions thereof

Publications (1)

Publication Number Publication Date
MX2019012336A true MX2019012336A (es) 2020-07-14

Family

ID=62111264

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012336A MX2019012336A (es) 2017-04-19 2018-04-17 Compuestos inhibidores del transportador vesicular de monoaminas 2 (vmat2) y composiciones de los mismos.

Country Status (16)

Country Link
US (1) US11040970B2 (es)
EP (1) EP3612532B1 (es)
JP (1) JP7170662B2 (es)
KR (1) KR20190140968A (es)
CN (1) CN110770236B (es)
AU (1) AU2018254429A1 (es)
BR (1) BR112019021853A2 (es)
CA (1) CA3060251A1 (es)
CL (1) CL2019002919A1 (es)
CO (1) CO2019011604A2 (es)
JO (1) JOP20190239A1 (es)
MA (1) MA50145A (es)
MX (1) MX2019012336A (es)
PE (1) PE20191784A1 (es)
TW (1) TW201841913A (es)
WO (1) WO2018195121A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3051832A1 (en) 2017-01-27 2018-08-02 Neurocrine Bioscienes, Inc. Methods for the administration of certain vmat2 inhibitors
TW201919622A (zh) 2017-09-21 2019-06-01 美商紐羅克里生物科學有限公司 高劑量戊苯那嗪（valbenazine）調配物及組合物、方法以及相關套組
EA202090932A1 (ru) 2017-10-10 2021-05-20 Нейрокрин Байосайенсиз, Инк Способы введения некоторых vmat2-ингибиторов
SG11202011544UA (en) * 2018-06-14 2020-12-30 Neurocrine Biosciences Inc Vmat2 inhibitor compounds, compositions, and methods relating thereto
JOP20200336A1 (ar) 2018-08-15 2020-12-22 Neurocrine Biosciences Inc طرق إعطاء مثبطات vmat2 معينة
TW202033521A (zh) * 2018-10-24 2020-09-16 美商紐羅克里生物科學有限公司 製備囊泡單胺轉運蛋白2(vmat2)抑制劑之方法
MX2022005651A (es) 2019-11-11 2022-07-27 Incyte Corp Sales y formas cristalinas de un inhibidor de la proteina de muerte celular programada 1 (pd-1)/ligando de muerte celular programada 1 (pd-l1).
CR20230448A (es) 2021-03-22 2023-10-27 Neurocrine Biosciences Inc Inhibidores de vmat2 y métodos de uso
WO2022232380A1 (en) 2021-04-29 2022-11-03 Neurocrine Biosciences, Inc. Processes for preparing a vmat2 inhibitor
CA3229341A1 (en) 2021-08-20 2023-02-23 Ryan TERRY-LORENZO Methods of screening for vmat2 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
NZ543863A (en) 2003-06-20 2009-05-31 Hoffmann La Roche Hexahydropyridoisoquinolines as DPP-IV inhibitors
CA2575979A1 (en) 2004-08-13 2006-02-23 Omeros Corporation Novel serotonin receptor ligands and their uses thereof
CA2668689C (en) * 2006-11-08 2015-12-29 Neurocrine Biosciences Inc. Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
FR2912145B1 (fr) 2007-02-02 2009-03-06 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2009126305A1 (en) 2008-04-11 2009-10-15 The Trustees Of Columbia University Glucose metabolism modulating compounds
NZ591615A (en) 2008-09-18 2012-07-27 Auspex Pharmaceuticals Inc Benzoquinoline inhibitors of vesicular monoamine transporter 2
US8772301B2 (en) 2009-12-18 2014-07-08 Sunovion Pharmaceuticals, Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
CN102285984B (zh) 2010-11-25 2012-10-10 江苏威凯尔医药科技有限公司 (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
EP2835372B1 (en) 2012-09-19 2016-05-04 Fujian Institute Of Research On The Structure Of Matter, Chinese Academy Of Sciences Thiophene [2, 3-d]pyrimidine derivative, and preparation method and use thereof
CN113413385A (zh) 2014-02-07 2021-09-21 纽罗克里生物科学有限公司 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途
ES2960717T3 (es) * 2015-02-06 2024-03-06 Neurocrine Biosciences Inc [9,10-Dimetoxi-3-(2-metilpropil)-1H,2H,3H,4H,6H,7H,11BH-pirido-[2,1-A]isoquinolin-2-il]metanol y compuestos, composiciones y métodos relacionados con el mismo
MX2019007651A (es) 2016-12-22 2020-02-07 Incyte Corp Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de internalizacion de ligando 1 de muerte programada (pd-l1).
EP3558985B1 (en) 2016-12-22 2022-09-07 Incyte Corporation Benzooxazole derivatives as immunomodulators

Also Published As

Publication number Publication date
BR112019021853A2 (pt) 2020-05-26
JOP20190239A1 (ar) 2019-10-09
AU2018254429A1 (en) 2019-11-07
US20200131173A1 (en) 2020-04-30
EP3612532A1 (en) 2020-02-26
EP3612532C0 (en) 2023-12-13
CN110770236B (zh) 2023-03-24
JP7170662B2 (ja) 2022-11-14
US11040970B2 (en) 2021-06-22
TW201841913A (zh) 2018-12-01
MA50145A (fr) 2020-07-29
CN110770236A (zh) 2020-02-07
CO2019011604A2 (es) 2019-10-31
KR20190140968A (ko) 2019-12-20
CA3060251A1 (en) 2018-10-25
PE20191784A1 (es) 2019-12-24
JP2020517607A (ja) 2020-06-18
EP3612532B1 (en) 2023-12-13
CL2019002919A1 (es) 2020-01-17
WO2018195121A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
MX2019012336A (es) Compuestos inhibidores del transportador vesicular de monoaminas 2 (vmat2) y composiciones de los mismos.
NZ733899A (en) [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
MX2021000795A (es) Compuestos heterociclicos para inhibir la actividad de shp2.
MX2020001776A (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
MX2022006475A (es) Compuestos triciclicos sustituidos.
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX2017010230A (es) Derivados de mono- y poliazanaftaleno sustituidos y su uso.
HUP0402454A2 (hu) Szubsztituált kinazolinszármazékok mint az aurora kinázok inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
MX2009004910A (es) Compuestos sustituidos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11-b- hexahidro-2h-pirido[2,1-a] isoquinolin-2-ol y métodos que se relacionan al mismo.
MX371167B (es) Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta).
MX2016006685A (es) Compuestos heterociclicos de n-acilimino.
MX2020010181A (es) Compuestos de piperidina como inhibidores covalentes de menina.
EA200601178A1 (ru) Морфолинилсодержащие бензимидазолы в качестве ингибиторов репликации респираторно-синцитиального вируса
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
TN2021000025A1 (en) Novel heterocyclic amine derivative and pharmaceutical composition comprising same
SG10201806809QA (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
MX2019008331A (es) Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.
MX2021001804A (es) Compuestos de urea y composiciones como inhibidores de atpasa de smarca2/brm.
EA201390374A1 (ru) Гетероциклические соединения для лечения или профилактики расстройств, вызываемых ослабленной нейротрансмиссией серотонина, норэпинефрина или допамина
CR20200643A (es) Nuev0s compuestos de piridina y pirazina com0 inhibidores del receptor connabinoide 2
MX2023003631A (es) Indazoles a manera de inhibidores de cinasa 1 progenitora hematopoyetica (hpk1) y metodos de uso de los mismos.
JOP20220084A1 (ar) مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
MX2022002339A (es) Derivados de alfa-d-galactopiranosido.
MX2016003630A (es) Compuestos heterociclicos de n-acilimino.
MX2023006176A (es) Nuevos derivados de indazol acetileno.